fbpx

West Chester, Pa, June 28, 2017—Molecular Targeting Technologies, Inc. (MTTI) announces that the publication* on TumorVue, by the University of Antwerp’s Molecular Imaging Center Antwerp (UAntwerp-MICA) and MTTI, was selected as the winner of the 2017 MILabs Image of the year at the 2017 Society of Nuclear Medicine and Molecular Imaging conference (SNMMI).  TumorVue™ (Tc-99m duramycin) can be used to detect treatment response as early as one day after a single administration of the drug. Recently, MTTI created DivineDx to commercialize TumorVue™.

Professor Freek Beekman, CEO of MILabs said, “We are excited by the excellent images of treatment response that can be shown with this new tracer-TumorVue™. Together with recent developments in very high resolution clinical SPECT this is a tremendous candidate game changer in nuclear medicine and personalized medicine.”

“Since the fraction of apoptotic cells in a tumor, even after effective chemotherapy, is limited,” said Professor Sigrid Stroobants, Head of Department of Nuclear Medicine of University Hospital of Antwerp, “it is encouraging to see that with TumorVue™ and a highly sensitive SPECT system that we can discriminate responders from non-responders.”

“Winning this prize is a confirmation of our work on the validation of TumorVue™ for early anti-cancer treatment evaluation. We are very excited about our preclinical findings and hope to translate this promising radiotracer to clinical practice soon”, said Professor Leonie wyffels of University of Antwerp.

Chris Pak, President and CEO of MTTI said, “We are honored to receive this prestigious 2017 MILabs Image of the Year Award for our product TumorVue™. We look forward to translating this robust molecule to the clinical stage. We believe this molecule can be used to distinguish drug responders from non-responders. This innovative agent will be a powerful tool for personalized medicine allowing cancer patients to be spared the toxicity of ineffective therapy.”

UAntwerpMICA-was founded in 2010 as a joint effort by the UAntwerp and the UZA and has become one of the front runners in translational from bench to patient-molecular imaging research.  UAntwerp is not an island: it builds bridges to secondary education, to industry and, by extension, to society as a whole. With over 5,000 members of staff, UAntwerp is one of the most important employers in Antwerp, Flanders’ largest city. More information: www.uantwerp.be

Molecular Targeting Technologies, Inc. (MTTI) is a privately held biotechnology company primarily focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.  More information: www.mtarget.com.

MILabs B.V. (Utrecht, the Netherlands) provides high-end molecular imaging solutions for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as diabetes, cancer, cardiac and neurodegenerative diseases. For more information, visit www.milabs.com

Contact: Chris Pak, Email: [email protected]; Tel: (610) 738-7938;
Peter Demeyer, Email: [email protected]
Freek Beekman,  Email: [email protected]; Tel:  +31 88 756 5343

 

###

*J Nucl Med. 2016 as doi:10.2967/jnumed.116.182014. 99mTc-duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with 18F-FDG PET.

Share on social media
Share on facebook
Share on twitter
Share on linkedin
Share on email

Miltenyi Biotec strengthens its research capabilities for cell analysis and preclinical imaging by acquiring a MILabs’ premium Optical/CT imaging system

  Utrecht and Bergisch Gladbach, September 9, 2020 Miltenyi Biotec B.V. & Co. KG, a …

Read More →

MILabs announced the co-winners of the MILabs Image of the Year Award

September 4, 2020, Utrecht, The Netherlands Each year, at the occasion of the Annual Congress …

Read More →

Bayer AS installs top-of-the-line MILabs VECTor PET/SPECT/CT to advance its targeted alpha therapy programs

August 27, 2020, Oslo-Norway and Utrecht-The Netherlands Bayer AS has installed a state-of-the-art MILabs VECTor …

Read More →

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam

Spotlight on Prof. Marion de Jong – Erasmus MC Rotterdam On the frontline of fighting …

Read More →

The University of Southampton enters the field of Correlative In-Vivo Imaging by acquiring MILabs 3D/4D Optical/CT

May 12, 2020, Southampton, UK – Utrecht, the Netherlands The Faculty of Medicine, University of …

Read More →

MILabs remotely installs from the Netherlands new E-Class PET/SPECT/CT at Osaka University of Pharmaceutical Sciences

Osaka, Japan and Utrecht, the Netherlands May 4th, 2020 In a world with COVID-19 travel …

Read More →

University of Torino (UNITO) acquires an advanced MILabs molecular imaging system

The University of Torino (UNITO) acquires advanced MILabs molecular imaging system for the design of …

Read More →

Truman VA acquires VECTor preclinical imaging system featuring exclusive multimodal synergy capabilities.

Columbia, Missouri, USA and Utrecht, the Netherlands April 9th, 2020 Harry S. Truman Memorial Veterans’ …

Read More →

Cyprus-based EPOS-Iasis acquires MILabs innovative Optical/CT system

Aimed at achieving a paradigm shift in Oncology research by imaging and quantifying fluorescent signals …

Read More →

MILabs enhances micro-CT for Coronavirus (COVID-19) research.

March 19, 2020 – Utrecht, the Netherlands Based on recent scientific research, diagnostic X-ray CT …

Read More →

The Julius Wolf Institute at the Charité installs mission-critical MILabs microCT for in-vivo studies of musculoskeletal regeneration

25 February 2020 – Berlin-Germany and Utrecht, Netherlands, The Julius Wolff Institute for Biomechanics and …

Read More →

MILabs realizes a breakthrough in preclinical oncology imaging by eliminating the positron range effect of 89Zr-immunoPET

February 15, 2020 – Utrecht, the Netherlands Researchers at MILabs B.V. have succeeded at imaging …

Read More →
Scroll to Top